Patents by Inventor Mark Saltzman

Patent number: 8889117
Abstract: Modular nanoparticle vaccine compositions and methods of making and using the same have been developed. Modular nanoparticle vaccine compositions comprise an antigen encapsulated in a polymeric particle and adaptor elements which modularly couple functional elements to the particle. The modular design of these vaccine compositions, which involves flexible addition and subtraction of antigen, adjuvant, immune potentiators, molecular recognition and transport mediation elements, as well as intracellular uptake mediators, allows for exquisite control over variables that are important in optimizing an effective vaccine delivery system.
Type: Grant
Filed: February 15, 2008
Issued: November 18, 2014
Assignee: Yale University
Inventors: Ira S. Mellman, Tarek M. Fahmy, William Mark Saltzman, Michael J. Caplan
Patent number: 8790317
Abstract: An embodiment of the invention is directed to a microfabricated, silicon-based, Convection Enhanced Delivery (CED) device. The device comprises a silicon shank portion, at least one individual parylene channel disposed along at least a part of an entire length of the shank, wherein the channel has one or more dimensioned fluid exit ports disposed at one or more respective locations of the channel and a fluid (drug) input opening. The fluid input opening may be configured or adapted to be connected to a fluid reservoir and/or a pump and/or a meter and/or a valve or other suitable control device(s) or apparatus that supplies and/or delivers fluid (eg, a drug) to the microfabricated device. The device may have multiple channels disposed side by side or in different surfaces of the device.
Type: Grant
Filed: February 12, 2008
Issued: July 29, 2014
Assignees: Cornell University, Yale University
Inventors: William L. Olbricht, Keith B. Neeves, Conor Foley, Russell T. Mattews, W. Mark Saltzman, Andrew Sawyer
Application number: 20110268810
Abstract: Polymeric microparticles are used to deliver recombinagenic or mutagenic nucleic acid molecules such as donor nucleic acid alone, or in combination with triplex-forming molecules, to induce a site-specific mutation in the target DNA. Target cells endocytose the particles, releasing the nucleic acid molecules inside of the cell, where they induce mutagenesis or recombination at a target site. The examples demonstrate that triplex forming oligonucleotides, preferably PNAs, preferably in combination with a donor nucleotide molecule, can be encapsulated into polymeric microparticles, which are delivered into cells. Results demonstrate significantly greatly levels of uptake and expression, and less cytotoxicity, as compared to direct transfer of the nucleic acid molecules into the cell by nucleofection.
Type: Application
Filed: November 2, 2010
Issued: November 3, 2011
Inventors: William Mark Saltzman, Peter M. Glazer, Joanna Chin, Nicole McNeer
Application number: 20100151436
Abstract: Methods for ex vivo administration of drugs to grafts using polymeric micro- and nanoparticles and applications for these methods are described herein. The particles contain encapsulated molecules which are released locally at the site of implantation and function to prevent graft rejection or aid in the proper adaptation of the graft to the host. The disclosed methods may be used to inhibit or reduce hyperplasia and stenosis of vascular grafts or to prevent graft rejection.
Type: Application
Filed: February 28, 2008
Issued: June 17, 2010
Inventors: Peter M. Fong, William Mark Saltzman, Tarek M. Fahmy
Application number: 20100104503
Abstract: Modular nanoparticle vaccine compositions and methods of making and using the same have been developed. Modular nanoparticle vaccine compositions comprise an antigen encapsulated in a polymeric particle and adaptor elements which modularly couple functional elements to the particle. The modular design of these vaccine compositions, which involves flexible addition and subtraction of antigen, adjuvant, immune potentiators, molecular recognition and transport mediation elements, as well as intracellular uptake mediators, allows for exquisite control over variables that are important in optimizing an effective vaccine delivery system.
Type: Application
Filed: February 15, 2008
Issued: April 29, 2010
Inventors: Ira S. Mellman, Tarek M. Fahmy, William Mark Saltzman, Michael J. Caplan
Application number: 20090269397
Abstract: Polymeric delivery devices have been developed which combine high loading/high density of molecules to be delivered with the option of targeting. As used herein, “high density” refers to microparticles having a high density of ligands or coupling agents, which is in the range of 1000-10,000,000, more preferably between 10,000 and 1,000,000 ligands per square micron of microparticle surface area. A general method for incorporating molecules into the surface of biocompatible polymers using materials with an HLB of less than 10, more preferably less than 5, such as fatty acids, has been developed. Because of its ease, generality and flexibility, this method has widespread utility in modifying the surface of polymeric materials for applications in drug delivery and tissue engineering, as well other fields.
Type: Application
Filed: May 18, 2009
Issued: October 29, 2009
Inventors: William Mark Saltzman, Tarek Fahmy, Peter Fong
Application number: 20090239789
Abstract: Polymeric microparticles have been developed which encapsulate therapeutic compounds such as drugs, cellular materials or components, and antigens, and can have targeting ligands directly bound to the microparticle surface. Preferred applications include use in tissue engineering matrices, wound dressings, bone repair or regeneration materials, and other applications where the microparticles are retained at the site of application or implantation. Another preferred application is in the use of microparticles to deliver anti-proliferative agents to the lining of blood vessels following angioplasty, transplantation or bypass surgery to prevent or decrease restenosis, and in cancer therapy. In still another application, the microparticles are used to treat or prevent macular degeneration when administered to the eye, where agents such as complement inhibitors are administered.
Type: Application
Filed: May 26, 2009
Issued: September 24, 2009
Assignee: Yale University
Inventors: William Mark Saltzman, Tarek Fahmy, Peter Fong
Patent number: 7550154
Abstract: Polymeric microparticles have been developed which encapsulate therapeutic compounds such as drugs, cellular materials or components, and antigens, and can have targeting ligands directly bound to the microparticle surface. Preferred applications include use in tissue engineering matrices, wound dressings, hone repair or regeneration materials, and other applications where the microparticles are retained at the site of application or implantation. Another preferred application is in the use of microparticles to deliver anti-proliferative agents to the lining of blood vessels following angioplasty, transplantation or bypass surgery to prevent or decrease restenosis, and in cancer therapy. In still another application, the microparticles are used to treat or prevent macular degeneration when administered to the eye, where agents such as complement inhibitors are administered.
Type: Grant
Filed: July 30, 2007
Issued: June 23, 2009
Assignee: Yale University
Inventors: William Mark Saltzman, Tarek Fahmy, Peter Fong
Patent number: 7534448
Abstract: Polymeric microparticles have been developed which encapsulate therapeutic compounds such as drugs, cellular materials or components, and antigens, and can have targeting ligands directly bound to the microparticle surface. Preferred applications include use in tissue engineering matrices, wound dressings, bone repair or regeneration materials, and other applications where the microparticles are retained at the site of application or implantation. Another preferred application is in the use of microparticles to deliver anti-proliferative agents to the lining of blood vessels following angioplasty, transplantation or bypass surgery to prevent or decrease restenosis, and in cancer therapy. In still another application, the microparticles are used to treat or prevent macular degeneration when administered to the eye, where agents such as complement inhibitors are administered.
Type: Grant
Filed: June 30, 2005
Issued: May 19, 2009
Assignee: Yale University
Inventors: William Mark Saltzman, Tarek Fahmy, Peter Fong, Chris Breuer
Patent number: 7534449
Abstract: Polymeric delivery devices have been developed which combine high loading/high density of molecules to be delivered with the option of targeting. As used herein, “high density” refers to microparticles having a high density of ligands or coupling agents, which is in the range of 1000-10,000,000, more preferably between 10,000 and 1,000,000 ligands per square micron of microparticle surface area. A general method for incorporating molecules into the surface of biocompatible polymers using materials with an HLB of less than 10, more preferably less than 5, such as fatty acids, has been developed. Because of its ease, generality and flexibility, this method has widespread utility in modifying the surface of polymeric materials for applications in drug delivery and tissue engineering, as well other other fields.
Type: Grant
Filed: June 30, 2005
Issued: May 19, 2009
Assignee: Yale University
Inventors: William Mark Saltzman, Tarek Fahmy, Peter Fong
Patent number: 7030097
Abstract: One aspect of the present invention relates to a nucleic acid delivery system including a polymeric structure formed of a biocompatible polymer and a mixture comprising one or more nucleic acid molecules and a first co-dispersant, the mixture being contained within the polymeric structure, wherein the first co-dispersant is present in an amount effective to control diffusion of the one or more nucleic acid from the polymeric structure. Compositions including the nucleic acid delivery system and a pharmaceutically-acceptable carrier are disclosed. Methods of making the nucleic acid delivery system and their use in delivering nucleic acid into a patient and modifying gene expression in a target cell are also disclosed.
Type: Grant
Filed: July 14, 2000
Issued: April 18, 2006
Assignee: Cornell Research Foundation, Inc.
Inventors: William Mark Saltzman, Dan Luo, Hong Shen, Kim Woodrow-Mumford, Nadya D. Belcheva
Application number: 20030149690
Abstract: A method and apparatus for searching all public datbases, indexing the results such that a CCTLD and GTLD indication is deleted, searching the indexed results in all non-public zone files and generating results wherein the apparatus is comprised of a processor having access to the world wide web and memory having instructions that when executed by the processor cause the computer system to perform the steps above.
Type: Application
Filed: January 31, 2003
Issued: August 7, 2003
Inventors: Mark E. Kudlacik, Mark Saltzman
Patent number: 6322815
Abstract: Polymeric drug conjugates in controlled release matrices are provided which allow sustained concentrations of therapeutic agents within a treated area for a prolonged period. The polymeric drug conjugates hydrolytically degrade in the extracellular space in a controlled, pre-specified pattern, releasing active drug. The conjugates diffuse within the tissue reaching a greater distance from the matrix than free drug would, because of their reduced rate of clearance from the tissue via the capillary system.
Type: Grant
Filed: July 22, 1994
Issued: November 27, 2001
Inventors: W. Mark Saltzman, O. Michael Colvin, Wenbin Dang, Susan Ludeman
Patent number: 6319715
Abstract: The present invention provides a method for enhancing the delivery of nucleic acid molecules to cells by increasing the concentration of cells at the cell surface. The method comprises the step of premixing of nucleic acid:vector molecules with nanoparticles that are biocompatible, reversibly associate with the nucleic acids and have a sedimentation rate which increases the concentration of the nucleic acids at the cell surface so as to enhance delivery into the cells.
Type: Grant
Filed: April 21, 2000
Issued: November 20, 2001
Assignee: Cornell Research Foundation, Inc.
Inventors: Dan Luo, W. Mark Saltzman, Ernest Han, Nadya Belcheva
Patent number: 5656271
Abstract: A genus specific chlamydia oral or injectable vaccine is provided which comprises an anti-idiotype antibody capable of producing in an animal an anti-idiotypic antibody or Fab fragment thereof enclosed in microspheres formed of a pharmacologically acceptable polymer is capable of producing in an animal an anti-anti-idiotypic immune response (serum antibody, secretory antibody or T-cell responsee) which recognizes a glycolipid exoantigen (GLXA) of chlamydia. The oral or injectable vaccine is produced from an idiotypic antibody to GLXA which, in turn, is utilized to produce the anti-idiotypic antibody.
Type: Grant
Filed: June 6, 1995
Issued: August 12, 1997
Assignees: The Johns Hopkins University, University of Massachusetts
Inventors: Alex Bruce MacDonald, Judith A. Whittum-Hudson, William Mark Saltzman